Human IL-13 Antibody

Catalog #: AF-213-NA
5 Citations 2 Reviews Datasheet

Catalog #	Availability	Size / Price	Qty
AF-213-NA
AF-213-SP

1 Image

All IL-13 Antibodies

Product Details

Citations (5)

FAQs

Supplemental Products

Reviews (2)

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IL-13 Antibody Summary

Species Reactivity

Human

Specificity

Detects human IL-13 in direct ELISAs and Western blots.

Source

Polyclonal Goat IgG

Purification

Antigen Affinity-purified

Immunogen

E. coli-derived recombinant human IL-13
Gly21-Asn132
Accession # AAK53823

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

0.1 µg/mL

Recombinant Human IL‑13 (Catalog # 213-ILB)

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Intracellular Staining by Flow Cytometry

5 µg/10⁶ cells

Human IL-13 transfected NS0 cells fixed with paraformaldehyde and permeabilized with saponin

Neutralization

Human IL-13 Antibody (Catalog # AF-213-NA) neutralizes Recombinant Human IL-13 (Catalog # 213-ILB) induced proliferation in the TF 1 human erythroleukemic cell line. The Neutralization Dose (ND₅₀) for this effect is typically <3.00 µg/mL in the presence of 10 ng/mL Recombinant Human IL-13.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

Neutralization by Human IL 13 Antibody Human IL-13 Antibody (Catalog # AF-213-NA) neutralizes Recombinant Human IL-13 (213-ILB) induced proliferation in the TF 1 human erythroleukemic cell line. The Neutralization Dose (ND₅₀) for this effect is typically < 3.00 µg/mL in the presence of 10 ng/mL Recombinant Human IL-13.

Preparation and Storage

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-13

IL-13 is a 17 kDa immunoregulatory cytokine that plays a key role in the pathogenesis of allergic asthma and atopy. It is secreted by Th1 and Th2 CD4⁺ T cells, NK cells, visceral smooth muscle cells, eosinophils, mast cells, and basophils (1-3). IL-13 circulates as a monomer with two internal disulfide bonds that contribute to a bundled four alpha -helix configuration (4, 5). Mature human IL-13 shares 57%, 59%, and 94% amino acid sequence identity with mouse, rat, and rhesus macaque IL-13, respectively. Despite the low homology, it exhibits cross-species activity between human, mouse, and rat (6, 7). IL-13 has diverse activities on numerous cell types (8). On macrophages, IL-13 suppresses the production of pro-inflammatory cytokines and other cytotoxic substances. On B cells, IL-13 induces immunoglobulin class switching to IgE, upregulates the expression of MHC class II, CD71, CD72, and CD23, and costimulates proliferation. IL-13 upregulates IL-6 while downregulating IL-1 and TNF-alpha production by fibroblasts and endothelial cells. IL-13 binds with low affinity to IL-13 R alpha 1, triggering IL-13 R alpha 1 association with IL-4 R alpha. This high affinity receptor complex also functions as the type 2 IL-4 receptor complex (9, 10). Additionally, IL-13 binds with high affinity to IL-13 R alpha 2 which is expressed intracellularly, on the cell surface, and as a soluble molecule (11-14). IL-13 R alpha 2 regulates the bioavailability of both IL-13 and IL-4 and is over-expressed in glioma and several bronchial pathologies (10, 15, 16). Compared to wild type IL-13, the atopy-associated R110Q variant of IL-13 elicits increased responsiveness from eosinophils that express low levels of IL-13 R alpha 2 (17).

References

Wills-Karp, M. (2004) Immunol. Rev. 202:175.
Nakajima H. and K. Takatsu (2007) Int. Arch. Allergy Immunol. 142:265.
McKenzie, A.N. et al. (1993) Proc. Natl. Acad. Sci. USA 90:3735.
Moy, F.J. et al. (2001) J. Mol. Biol. 310:219.
Eisenmesser, E.Z. et al. (2001) J. Mol. Biol. 310:231.
Ruetten, H. and C. Thiemermann (1997) Shock 8:409.
Lakkis, F.G. et al. (1997) Biochem. Biophys. Res. Commun. 235:529.
Wynn, T.A. (2003) Annu. Rev. Immunol. 21:425.
Andrews, A.L. et al. (2002) J. Biol. Chem. 277:46073.
Tabata, Y. et al. (2007) Curr. Allergy Asthma Rep. 7:338.
Chiaramonte, M.G. et al. (2003) J. Exp. Med. 197:687.
Daines, M.O. and G.K. Hershey (2002) J. Biol. Chem. 227:10387.
Matsumura, M. et al. (2007) Biochem. Biophys. Res. Commun. 360:464.
Tabata, Y. et al. (2007) J. Immunol. 177:7905.
Andrews, A.L. et al. (2006) J. Allergy Clin. Immunol. 118:858.
Joshi, B.H. et al. (2006) Vitam. Horm. 74:479.
Andrews, A-L. et al. (2007) J. Allergy Clin. Immunol. 120:91.

Long Name

Interleukin 13

Entrez Gene IDs

3596 (Human); 16163 (Mouse); 116553 (Rat); 574325 (Primate)

Alternate Names

ALRHMGC116789; BHR1interleukin-13; IL13; IL-13; IL-13MGC116788; interleukin 13; MGC116786; NC30; P600

Product Datasheets

Product Datasheet

Related Research Areas

Citations for Human IL-13 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

5 Citations: Showing 1 - 5
Filter your results:

Filter by:

Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice
Authors: E Conde, R Bertrand, B Balbino, J Bonnefoy, J Stackowicz, N Caillot, F Colaone, S Hamdi, R Houmadi, A Loste, JBJ Kamphuis, F Huetz, L Guillemina, N Gaudenzio, A Mougel, D Hardy, JN Snouwaert, BH Koller, V Serra, P Bruhns, G Grouard-Vo, LL Reber
Nature Communications, 2021-05-11;12(1):2574.
Species: Human
Sample Types: Recombinant Proteins
Applications: Western Blot
Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells.
Authors: Liu TY, Uemura Y, Suzuki M, Narita Y, Hirata S, Ohyama H, Ishihara O, Matsushita S
Eur. J. Immunol., 2008-04-01;38(4):1012-23.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
Histological characteristics and altered expression of interleukins (IL) IL-13 and IL-15 in endometria of levonorgestrel users with different uterine bleeding patterns.
Authors: Rhoton-Vlasak A, Hardt N
Fertil. Steril., 2005-03-01;83(3):659-65.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P
Differential expression of interleukins IL-13 and IL-15 in normal ovarian tissue and ovarian carcinomas.
Authors: Ripley D, Shoup B, Majewski A
Gynecol. Oncol., 2004-03-01;92(3):761-8.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P
Human lung myofibroblasts as effectors of the inflammatory process: the common receptor gamma chain is induced by Th2 cytokines, and CD40 ligand is induced by lipopolysaccharide, thrombin and TNF-alpha.
Authors: Doucet C, Giron-Michel J, Canonica GW, Azzarone B
Eur. J. Immunol., 2002-09-01;32(9):2437-49.
Species: Human
Sample Types: Whole Cells
Applications: ICC